linjc16/ctgov huggingface dataset:
Brucella Serology and History of Brucellosis in Patients With Modic Changes Type 1

Study Overview
=================
Brief Summary
-----------------
Objective: This study aims to examine Brucella serology and history of brucellosis in patients with lumbar Modic changes (MCs) type 1, considering results from cross-sectional and case-control comparisons. Design: In comparative cross-sectional design, MCs type 1 patients (study group) and MCs type 2 patients (comparator group) were examined in terms of Brucella serology by using agglutination with Coombs test. In addition, in comparative case-control design, both of the MCs groups and age/sex-matched healthy controls were investigated for their medical history regarding brucellosis.

Official Title
-----------------
Mehmet Akif İnan Education and Research Hospital

Conditions
-----------------
Brucellosis, Spinal Degeneration

Intervention / Treatment
-----------------
* Other: Brucella serology test
* Other: Medical history for brucellosis


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with lumbar Modic changes type 1 Patients with lumbar Modic changes type 2 Participant who given informed consent for the study Exclusion Criteria: Patients aged<18 years History of serious lumbar trauma Lumbar spinal surgery Scoliosis Cooperation disorder

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| MCs type 1 patients (study group; n=37)<br> | Other: Brucella serology test<br>* MCs type 1 and type 2 patients were examined in terms of Brucella serology by using agglutination with Coombs test.<br>Other: Medical history for brucellosis<br>* Both of the MCs groups and healthy controls were investigated for their medical history regarding brucellosis.<br>|
| MCs type 2 patients (comparator group; n=44)<br> | Other: Brucella serology test<br>* MCs type 1 and type 2 patients were examined in terms of Brucella serology by using agglutination with Coombs test.<br>Other: Medical history for brucellosis<br>* Both of the MCs groups and healthy controls were investigated for their medical history regarding brucellosis.<br>|
| healthy controls (n=37)<br> | Other: Medical history for brucellosis<br>* Both of the MCs groups and healthy controls were investigated for their medical history regarding brucellosis.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Serology for brucellosis |  | 30 minutes | 
| History of brucellosis |  | 7 minutes |
Multicenter and Prospective Clinical Registry Study of Anti-N-methyl-D-aspartate Receptor Encephalitis in Beijing Area

Study Overview
=================
Brief Summary
-----------------
Anti N-methyl-D-aspartate receptor encephalitis is an autoimmune encephalitis，found in recent years，producing the specific IgG antibody induced by the NMDA receptors.It is the most common curable disease among the non infectious-autoimmune encephalitis,usually has been misdiagnosed as other causes of encephalitis.Our previous study found that there are differences between the Chinese and the foreign in anti-NMDA receptor encephalitis such as the sex ratio, the rate of combined tumor and clinical manifestations.As a new found disease,the incidence rate has been underestimated.Therefore,to establish the Registry Research Database for Chinese group of anti-NMDA receptor encephalitis is imminent.This study will combine Beijing area's hospitals and foreign experts,depending on multicenter, prospective and registry method,to understand the incidence in Beijing area,to summarize and analyze the clinical data of patients.So,there will make a solid foundation for the subsequent Beijing area detection platform and other research.

Conditions
-----------------
Anti-N-Methyl-D-Aspartate Receptor Encephalitis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Older than 6 months. Encephalopathy symptoms (change of mental state and consciousness level) persist for more than 24 hours; At least one or more clinical features of the followings: fever, epilepsy, focal neurological deficiency symptoms, changes in CSF(cerebrospinal fluid inflammatory), changes in EEG (electroencephalogram), radiographic abnormalities; Clinical suspected encephalitis, but conventional detected methods cannot make etiology clear Exclusion Criteria: Infants less than 6 months; The metabolic encephalopathy; Infectious encephalitis with clinically clear pathogen, referring the specific pathogenic microorganisms, including: bacteria, virus, fungus, parasite, spirochete and so on; Non-infectious encephalitis with clinically clear diagnosis, including: multiple sclerosis, optic neuromyelitis, acute disseminated encephalomyelitis and so on.

Ages Eligible for Study
-----------------
Minimum Age: 6 Months

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| death |  | 24 months |
Safety and Efficacy of Zemplar Capsule in Reducing Serum IPTH Levels in Chronic Kidney Disease Subjects (Three Times Weekly)

Study Overview
=================
Brief Summary
-----------------
The objective of this study is to determine whether paricalcitol is safe and effective compared to placebo in reducing elevated serum PTH levels in patients with chronic kidney disease.

Official Title
-----------------
Safety and Efficacy of Zemplar Capsule in Reducing Serum IPTH Levels in Chronic Kidney Disease Subjects (Three Times Weekly)

Conditions
-----------------
Renal Insufficiency, Chronic

Intervention / Treatment
-----------------
* Drug: paricalcitol


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Under care of physician at least 2 months (for CKD) Not on active Vitamin D therapy for at least 4 weeks prior If female: Not of childbearing potential, OR Practicing birth control Not breastfeeding If taking phosphate binders, on a stable regimen at least 4 weeks prior For entry into Pretreatment Phase: iPTH at least 120 pg/mL GFR of 15-60 mL/min and no dialysis expected for at least 6 months For entry into Treatment Phase: Average of 2 consecutive iPTH values of at least 150 pg/mL, taken at least 1 day apart (all values not less than 120 pg/mL 2 consecutive corrected serum calcium levels between 8.0-10.0 mg/dL 2 consecutive serum phosphorus levels of not more than 5.2 mg/mL Exclusion Criteria: History of allergic reaction or sensitivity to similar drugs Acute Renal Failure within 12 weeks of study Chronic gastrointestinal disease Spot urine result demonstrating a urine-calcium-to-urine creatinine ratio of greater than 0.2, or a history of renal stones Taken aluminum-containing phosphate binders within last 12 weeks, or requires such medication for more than 3 weeks during study Current malignancy, or clinically significant liver disease Active granulomatous disease (TB, sarcoidosis, etc.) History of drug or alcohol abuse within 6 mos. prior Evidence of poor compliance with diet or medication Received any investigational drug or participated in any device trial within 30 days prior Taking maintenance calcitonin, bisphosphonates, or drugs that may affect calcium or bone metabolism (other than females on stable estrogen and/or progestin therapy) On glucocorticoids for a period of more than 14 days within the last 6 months HIV positive

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: paricalcitol|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The efficacy endpoint is achievement of two consecutive > or = 30% decreases from baseline iPTH levels. |  |  |
Socket Shield With Immediate Implant Stability

Study Overview
=================
Brief Summary
-----------------
To evaluate socket shield technique either placing implant in direct contact to tooth fragment versus gap created between the tooth and implant.

Detailed Description
-----------------
Patients with a non-restorable tooth located in anterior maxillary arch was included in this study, patients were divided into two groups, eight implants per group, both groups had socket shield, group 1 will have implant in direct contact with shield, second group had a gap between dental implant and shield. soft tissue stability, bone width and implant stability was assessed preoperatively, immediate and 6 months postoperative.

Official Title
-----------------
Evaluation of Soft Tissue Stability and Labial Plate of Bone of Immediate Implant in Direct Contact Versus Gap With Socket Shield (A Randomized Clinical Study)

Conditions
-----------------
Dental Implant

Intervention / Treatment
-----------------
* Device: Dental implant


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with a non-restorable tooth located in anterior maxillary arch (upper right second premolar to upper left second premolar). Tooth to be extracted is endodontically treated and free from periapical infection. Systemic free patients according to modified Cornell medical index (Brodmank and Erdmann 1949). Patients with good compliance. Exclusion Criteria: Teeth with current acute periapical infection or sinus tracts. Heavy smokers and patients with bruxism habits. Patients with poor oral hygiene or not willing to perform oral hygiene measures. Vulnerable groups (as pregnant females and decisionally impaired individuals).

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Socket shield in direct contact with dental implant<br>eight partially extracted sockets where implant (Neobiotech) was placed in direct contact to socket shield | Device: Dental implant<br>* Comparative<br>|
| Active Comparator: Socket shield with gap and xenograft with dental implant<br>eight partially extracted sockets where a gap was left between implant (Neobiotech) and socket shield | Device: Dental implant<br>* Comparative<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Soft tissue stability | Pink esthetic score | 6 months postoperatively | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Bone stability | By Ostell | 6 months postoperatively |
An Open-Label Multicentre Long-Term Extension Study of Etanercept for Ankylosing Spondylitis

Study Overview
=================
Brief Summary
-----------------
This study is an extension trial of 0881A3-312-EU and is designed to provide information on the safety and efficacy of etanercept in patients with ankylosing spondylitis for up to 3 additional years.

Official Title
-----------------
An Open-Label Multicentre Long-Term Extension Study of Etanercept in Ankylosing Spondylitis

Conditions
-----------------
Ankylosing Spondylitis

Intervention / Treatment
-----------------
* Drug: Enbrel (Etanercept)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Completed study 0881A3-312-EU Agreeable to utilize medically acceptable form of contraception Able to reconstitute and self-inject or have a designee Exclusion Criteria: Withdrawn from study 0881A3-312-EU Abnormal hematology or chemistry profiles Clinically relevant medical conditions including: congestive heart failure, multiple sclerosis or other central demyelinating diseases, blood dyscrasias, cancer or serious infection

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Enbrel (Etanercept)|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To evaluate the long-term safety of etanercept in adults with ankylosing spondylitis who have completed study 0881A3-312-EU. |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To assess the long-term clinical efficacy of etanercept in these study subjects. |  |  |
Ultra-low-dose Chest CT for HHT

Study Overview
=================
Brief Summary
-----------------
This study aims to develop a novel ultra-low dose chest CT technology for use in Hereditary Hemorrhagic Teleangiectasia (HHT) patients and to determine the lowest possible radiation dose that is achievable without sacrificing the diagnostic quality.

Official Title
-----------------
Novel Ultra-low-dose Chest CT Technique to Screen for Pulmonary Arteriovenous Malformations in Pediatric Patients With Hereditary Hemorrhagic Teleangiectasia

Conditions
-----------------
Hereditary Hemorrhagic Telangiectasia

Intervention / Treatment
-----------------
* Diagnostic Test: Ultra-low dose chest CT


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Ages 1 to 17 years Diagnosed with positive HHT causing mutations or based on Curacao criteria Exclusion Criteria: Acute respiratory distress Unstable cardiovascular status Pneumothorax, hemoptysis Pulmonary edema Pulmonary emboli Fractured ribs or other chest trauma Recent bronchoscopy Lung transplantation

Ages Eligible for Study
-----------------
Minimum Age: 1 Year
Maximum Age: 17 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Low-dose contrast-enhanced chest CT exam<br>Subjects will undergo a low-dose contrast-enhanced chest CT exam with coverage from the neck base through the lungs to the upper abdomen on a third-generation dual-source CT scanner as part of their routine clinical visit based on current guidelines. | Diagnostic Test: Ultra-low dose chest CT<br>* A novel CT technique with a new dose optimization and efficiency technology and automatic kV selection, which greatly reduces the dose of radiation exposure compared to a standard chest CT.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Ultra-low dose images PAVM detection | Number of images detecting PAVM using the ultra-low dose images (50% or lower compared to the full dose) | Baseline |
Residual Symptoms After Coronavirus Disease (COVID-19) in Lithuanian Population

Study Overview
=================
Brief Summary
-----------------
The aim of the study is to describe the post-covid-19 syndrome in Lithuanian population regarding the remaining symptoms and their impact on physical functioning, work ability and needs of rehabilitation.

Detailed Description
-----------------
Participants with suspected and confirmed cases of COVID-19 infection will complete an anonymous online questionnaire for post-covid syndrome, i.e. symptoms lasting longer than 28 days after post-covid-19 syndrome. The online survey is developed to assess the health state before infection and residual symptoms lasting longer than acute COVID-19 infection, influencing the functional activity and work ability. The needs of rehabilitation will also be assessed.

Official Title
-----------------
Residual Symptoms in Patients With a History of Coronavirus Disease (COVID-19) and Their Impact on Biopsychosocial Functions (Post-Covid Syndrome)

Conditions
-----------------
Post-Covid Syndrome

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: older than 18 years age patients; a history of COVID-19 infection that was and was not positive for SARS-CoV-2 diagnostic or antibody testing the duration of remaining symptoms is longer than 28 days ability to fulfil internet-based questionnaire Exclusion Criteria: ongoing covid-19 infection other comorbidities requiring treatment or rehabilitation

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Description of post-covid-19 syndrome in Lithuanian population | Post-covid-19 syndrome in Lithuanian population: prevalence, symptomatology and needs of rehabilitation | 2021.05.04 - 2022.12.31 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Assessment of medical premorbid status in post-covid-19 syndrome | The severity of comorbidities in terms of self-reported medical diagnoses and medication | 2021.05.04 - 2022.12.31 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Post-Covid syndrome; Rehabilitation
Evaluation of the Right Use of Inhaled Therapeutics

Study Overview
=================
Brief Summary
-----------------
Asthma and COPD have a significant impact on public health, affecting about 8 million people in France and generating health care costs of 5.5 billion euros, almost 50% of which are dedicated to long-term treatments are essentially inhaled therapies. The good control of the disease depends on the patient's compliance, but also on the proper use of the devices used for the administration of inhaled drugs under penalty of the degradation of the control of the disease with major medical and medico-economic consequences. Thus, education of these patients in the use of devices must be an integral part of medical care. It comes up against the complexity of the therapeutic arsenal on the one hand and on the other hand with its time-consuming nature: this makes it incompatible with a realization in consultation. The ARGOS process is a telemonitoring project for the support of therapeutic education, consisting in setting up a concrete and real-time relay between prescribers and patients for the education of inhaled therapeutics. Its objective is to provide the answer to what is currently an unmet need in the management of asthma and COPD, with the prospect of a positive impact on the observance of these treatments and by consequently their clinical and economic efficiency.

Official Title
-----------------
Evaluation of the Right Use of Inhaled Therapeutics Prescribed in Asthma and COPD in Adults

Conditions
-----------------
COPD Asthma

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient followed in Pneumology for asthma or COPD with a prescription for long-term inhaled therapies AND a home health provider (who monitors either home oxygen and / or respiratory equipment) The patient must have a means of telephone communication in order to be able to be contacted by a provider, an H2AD permanence or a doctor Patient having given his agreement after having been informed in writing of the purpose and the data collected during this study Age ≥ 18 years Beneficiary of a social security scheme Exclusion Criteria: Refusal of the patient Patient not understanding French Absence of home health provider Absence of means of telephone communication

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Percentage of exploitable films | Ratio between the number of exploitable films and the number of films arriving at the telemedicine platform. | Day 1 to day 7 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
COPD, Asthma, Inhaled Therapeutics